NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$13.26
+0.45 (+3.51%)
Open$13.11
Previous Close$12.81
Day High$13.67
Day Low$13.03
52W High$28.25
52W Low$5.90
Volume—
Avg Volume3.08M
Market Cap1.52B
P/E Ratio—
EPS$-3.83
SectorBiotechnology
Analyst Ratings
Hold
30 analysts
Price Target
+145.2% upside
Current
$13.26
$13.26
Target
$32.51
$32.51
$20.88
$32.51 avg
$45.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 72.02M | 66.02M | 223.20M |
| Net Income | -439,247,645 | -362,382,326 | -30,251,127 |
| Profit Margin | -609.9% | -579.4% | -13.6% |
| EBITDA | -458,972,263 | -399,691,676 | -52,265,042 |
| Free Cash Flow | — | — | -47,461,783 |
| Rev Growth | +9.1% | +9.1% | +19.1% |
| Debt/Equity | — | — | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |